Nanobiotix
ISIN: FR0011341205 | Ticker: NANO | LEI: 969500667RSYIH8YL895
Country: France
Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.
Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
2003
Served areaWorldwide
Headcount110
Headquarters60 Rue de Wattignies, 75012 Paris – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 134,030,000.00 | 101,769,000.00 | 59,769,000.00 |
| Noncurrent Assets | N/A | 8,782,000.00 | 8,709,000.00 | 7,412,000.00 |
| Property Plant And Equipment | N/A | 8,256,000.00 | 8,186,000.00 | 7,120,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 21,000.00 | 4,000.00 | 1,000.00 |
| Current Assets | N/A | 125,248,000.00 | 93,060,000.00 | 52,358,000.00 |
| Current Trade Receivables | N/A | 62,000.00 | 0.00 | 101,000.00 |
| Cash and cash equivalents | 35,094,000.00 | 119,151,000.00 | 83,921,000.00 | 41,388,000.00 |
| Other Current Assets | N/A | 6,035,000.00 | 9,139,000.00 | 10,868,000.00 |
| Equity And Liabilities | N/A | 134,030,000.00 | 101,769,000.00 | 59,769,000.00 |
| Equity | -1,908,000.00 | 70,468,000.00 | 26,790,000.00 | -27,045,000.00 |
| Issued Capital | N/A | 1,033,000.00 | 1,045,000.00 | 1,046,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -47,003,000.00 | -57,041,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | -183,459,000.00 | -227,282,000.00 |
| Share Premium | N/A | 255,735,000.00 | 255,767,000.00 | 255,760,000.00 |
| Treasury Shares | N/A | 196,000.00 | 202,000.00 | 228,000.00 |
| Other Reserves | N/A | -153,069,000.00 | -183,459,000.00 | N/A |
| Noncurrent Liabilities | N/A | 44,522,000.00 | 38,134,000.00 | 48,878,000.00 |
| Noncurrent Provisions | N/A | 414,000.00 | 318,000.00 | 270,000.00 |
| Current Liabilities | N/A | 19,041,000.00 | 36,845,000.00 | 37,936,000.00 |
| Current Provisions | N/A | 40,000.00 | 110,000.00 | 327,000.00 |
| Trade And Other Current Payables | N/A | 7,106,000.00 | 6,482,000.00 | 9,621,000.00 |
| Current Contract Liabilities | N/A | 0.00 | 16,518,000.00 | 16,518,000.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | N/A | 254,000.00 | 55,000.00 |
| Other Current Liabilities | N/A | 7,022,000.00 | 5,277,000.00 | 6,855,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 2,512,000.00 | 2,647,000.00 | 4,776,000.00 |
| Revenue From Contracts With Customers | 50,000.00 | 10,000.00 | 0.00 |
| Other Income | 2,462,000.00 | 2,637,000.00 | 4,776,000.00 |
| Profit Loss From Operating Activities | -36,428,000.00 | -52,579,000.00 | -46,702,000.00 |
| Finance Income | 201,000.00 | 6,360,000.00 | 3,533,000.00 |
| Finance Costs | -2,646,000.00 | 780,000.00 | 13,863,000.00 |
| Income Tax Expense Continuing Operations | 9,000.00 | 5,000.00 | 10,000.00 |
| Profit (loss) | -33,590,000.00 | -47,003,000.00 | -57,041,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -33,590,000.00 | -47,003,000.00 | -57,041,000.00 |
| Adjustments For Finance Costs | N/A | 2,115,000.00 | 2,224,000.00 | 2,042,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 1,754,000.00 | 1,560,000.00 | 1,500,000.00 |
| Adjustments For Provisions | N/A | -48,000.00 | 152,000.00 | 305,000.00 |
| Adjustments For Sharebased Payments | N/A | 2,924,000.00 | 3,201,000.00 | 3,174,000.00 |
| Other Adjustments For Noncash Items | N/A | 7,000.00 | 8,000.00 | -36,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -27,538,000.00 | -29,872,000.00 | -37,104,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 96,000.00 | 228,000.00 | 92,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 11,000.00 | 5,000.00 | 1,000.00 |
| Proceeds From Other Longterm Assets Classified As Investing Activities | N/A | N/A | N/A | 230,000.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | N/A | 4,000.00 | 9,000.00 | N/A |
| Cash Flows From Used In Investing Activities | N/A | -112,000.00 | -242,000.00 | 138,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 10,350,000.00 | 0.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 250,000.00 | 2,833,000.00 | 3,642,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 928,000.00 | 909,000.00 | 1,093,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 700,000.00 | 1,132,000.00 | 915,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 111,769,000.00 | -5,180,000.00 | -5,651,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -63,000.00 | 64,000.00 | 83,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 84,056,000.00 | -35,230,000.00 | -42,533,000.00 |
| Cash and cash equivalents | 35,094,000.00 | 119,151,000.00 | 83,921,000.00 | 41,388,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 11.05.22 | None | Other | Other | EUR 0.00 |
FR0011341205
LEI969500667RSYIH8YL895
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.